Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR17 | Q13304 | 4/20 | 0.54 |
| ▸ | PARP1 | P09874 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | TPX2 | Q9ULW0 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | FBP1 | P09467 | 1/20 | 0.42 |
| ▸ | PLAU | P00749 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | RHEB | Q15382 | 3/20 | 0.40 |
| ▸ | GOT1 | P17174 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9936557 | 0.84 | ALDH1A1 (0.45) | GPR17HPGDAURKATPX2ALDH1A1 | |
| SCHEMBL34468456 | 0.83 | SLC6A4 (0.39) | GPR17AURKATPX2ALDH1A1RHEB | |
| SCHEMBL16540415 | 0.79 | GPR84 (0.61) | GPR17HPGDCYP2C19GPR84 | |
| SCHEMBL22783757 | 0.77 | ALDH1A1 (0.50) | PARP1AURKATPX2ALDH1A1RHEB | |
| SCHEMBL27644456 | 0.76 | PARP1 (0.68) | GPR17PARP1HPGDCYP2C19ALDH1A1 | |
| SCHEMBL12432714 | 0.76 | ALDH1A1 (0.42) | GPR17PARP1HPGDAURKATPX2 | |
| SCHEMBL2310325 | 0.74 | CMA1 (0.62) | — | |
| SCHEMBL1418003 | 0.72 | HIF1A (0.59) | GPR17HPGDCYP2C19PLAUFFAR1 | |
| SCHEMBL25254260 | 0.71 | RHEB (0.50) | HPGDAURKATPX2ALDH1A1RHEB | |
| SCHEMBL1614234 | 0.71 | SLC6A4 (0.60) | GPR17HPGDCYP2C19GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260115199-A1 | TRICYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2026-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260115199-A1 | TRICYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCCS, CCR6 | GPR17 1244/4885PARP1 1415/4885HPGD 2369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.